WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year

Core Insights - WuXi Biologics has been included in the S&P Global Sustainability Yearbook 2026 for the fourth consecutive year, achieving a Top 1% S&P Global Corporate Sustainability Assessment (CSA) Score, ranking first in its industry [1][1][1] Group 1: Company Performance - The company was recognized among 848 top performers out of over 9,200 companies assessed in the 2025 CSA [1][1] - WuXi Biologics' CEO, Dr. Chris Chen, emphasized the company's commitment to enhancing sustainability performance and delivering ESG excellence [1][1] Group 2: Sustainability Initiatives - WuXi Biologics is a participant in the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), advocating for sustainability [1][1] - The company has received multiple recognitions, including an MSCI AAA Rating, EcoVadis Platinum Medal, and inclusion in the Dow Jones Sustainability Indices [1][1][1] Group 3: Operational Overview - WuXi Biologics employs over 12,000 skilled employees across various countries and supports 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing as of December 31, 2025 [1][1] - The company aims to become an ESG leader in the biologics CRDMO sector, utilizing next-generation biomanufacturing technologies and clean-energy sources [1][1]